Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 9/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193927 | 0.86 | AKR1B1 (0.46) | AKR1B1HTR1DHTR1BCA2MAOB | |
| SCHEMBL20274118 | 0.86 | AKR1B1 (0.46) | AKR1B1HTR1DHTR1BCA2MAOB | |
| SCHEMBL8257436 | 0.83 | AKR1B1 (0.37) | AKR1B1CA2MAOBHTR2AHTR2C | |
| SCHEMBL8259596 | 0.82 | BACE1 (0.37) | AKR1B1CA2ACHEMAOB | |
| SCHEMBL20297420 | 0.80 | AKR1B1 (0.41) | AKR1B1CA2HTR2AHTR2CMEN1 | |
| SCHEMBL20297421 | 0.80 | AKR1B1 (0.41) | AKR1B1CA2HTR2AHTR2CMEN1 | |
| SCHEMBL5548007 | 0.79 | MAOA (0.35) | AKR1B1TP53 | |
| SCHEMBL5548009 | 0.79 | MEN1 (0.46) | MEN1KMT2ALMNATP53MAPT | |
| SCHEMBL13072472 | 0.79 | HRH3 (0.38) | AKR1B1ACHEMEN1KMT2ALMNA | |
| SCHEMBL2056484 | 0.79 | HTR2A (0.39) | AKR1B1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | AKR1B1 225/4885HTR1D 1586/4885HTR1B 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.